SARS-CoV-2, the virus behind COVID-19, stands apart from other common respiratory viruses in several concrete ways: how tightly it latches onto human cells, how widely it spreads through the body beyond the lungs, and how effectively it hides from your immune system in the critical early days of infection. Many of these differences stem from a single protein on the virus’s surface and the specific human receptor it targets.
A Spike Protein Built for Tight Binding
Every virus needs a way to get inside your cells, and SARS-CoV-2 does this exceptionally well. Its spike protein locks onto a receptor called ACE2, which sits on the surface of cells throughout your body. The original SARS virus from 2003 used the same receptor, but SARS-CoV-2 binds to it roughly 5 to 10 times more tightly. In lab measurements, SARS-CoV-2 grips ACE2 at concentrations around 30 to 50 nanomolar, compared to 180 to 400 nanomolar for the older SARS virus. A lower number means a stronger hold.
This isn’t just a matter of stickiness. When SARS-CoV-2 latches on, it physically changes the shape of the ACE2 receptor in a way the original SARS virus does not. The receptor hinges closed by about 5 degrees, compared to a negligible 0.3 degrees with SARS. That structural shift helps the virus enter cells more efficiently. Influenza, by contrast, uses an entirely different entry point, a sugar molecule called sialic acid found mainly in the airways. SARS-CoV-2’s reliance on ACE2 is one reason it can reach organs that flu typically cannot.
It Attacks Far More Than the Lungs
Most respiratory viruses stay in the respiratory tract. Influenza primarily damages the airways and lungs. SARS-CoV-2 can do the same, but its use of ACE2 gives it a much wider reach, because ACE2 receptors appear on cells in the heart, kidneys, blood vessels, intestines, and brain.
More than a quarter of critically ill COVID patients show signs of heart muscle injury, either at the time of diagnosis or as the illness worsens. The virus can also cause acute kidney injury and, in severe cases, multi-organ failure. Neurological effects are particularly distinctive. ACE2 is expressed in cortical neurons and supporting brain cells, which helps explain symptoms like loss of smell and cognitive difficulties that were rarely associated with common respiratory infections before the pandemic. The virus has been detected in brain tissue and cerebrospinal fluid, confirming it can cross from the respiratory tract into the central nervous system.
Stealth Spreading Before Symptoms Appear
One of the most consequential differences between COVID-19 and flu is the timing of contagiousness relative to symptoms. SARS-CoV-2 has a median incubation period of about 4.8 days, with 95% of people developing symptoms within 14 days. That’s roughly twice as long as seasonal flu, where viral levels peak 2 to 3 days after exposure and drop to undetectable levels by day 6 or 7.
Peak infectivity for SARS-CoV-2 falls between 2 days before and 1 day after symptoms start. This presymptomatic window is what made COVID so difficult to contain. People were at their most contagious before they had any reason to stay home. Meta-analyses found that presymptomatic individuals transmitted the virus at a rate of about 5% per 100 person-days of contact, comparable to symptomatic people (5.27%). Truly asymptomatic carriers, those who never developed symptoms, transmitted at a lower rate of about 1.8%, but they still contributed to spread because they were never identified as sick.
A Large, Self-Correcting Genome
Coronaviruses carry the largest genomes of any RNA virus, around 30,000 genetic letters (30 kilobases). For comparison, influenza’s genome is only about 13,500 letters, and it’s split across eight separate segments. That segmented design is why flu can reshuffle its genes dramatically when two different strains infect the same cell, a process behind occasional pandemic flu strains.
SARS-CoV-2’s genome is one continuous strand, so it can’t do that kind of wholesale genetic swap. It also mutates more slowly than flu. The spike gene of SARS-CoV-2 accumulates roughly 0.8 to 1.1 mutations per site per thousand years of evolution, while influenza’s key surface genes mutate about five times faster. SARS-CoV-2 achieves this relative stability because coronaviruses carry a proofreading enzyme that catches and corrects copying errors, something influenza lacks entirely. Despite this slower baseline rate, SARS-CoV-2 still generated significant variants (Alpha, Delta, Omicron) because it infected so many people so quickly, giving the virus billions of opportunities to stumble onto advantageous changes.
Suppressing Your Early Warning System
When a virus enters your body, one of the first lines of defense is a set of signaling molecules called type I interferons. These molecules act as an alarm, telling neighboring cells to activate their antiviral defenses and calling in immune cells. Most viruses trigger this alarm within hours.
SARS-CoV-2 is unusually good at delaying it. The virus produces multiple proteins that interfere with different steps of the interferon response. One blocks the cell’s ability to make its own proteins, effectively silencing the alarm at the manufacturing level. Another disrupts the signaling chain that would normally activate interferon genes. This delay gives the virus a head start, allowing it to replicate and spread to new cells before your immune system mounts a full response. When the immune reaction finally kicks in, it can overshoot, producing the excessive inflammation that drives severe COVID pneumonia and organ damage. This pattern of delayed-then-excessive immune response is more pronounced with SARS-CoV-2 than with most common respiratory viruses.
Staying Infectious in the Air and on Surfaces
SARS-CoV-2 is notably stable outside the body. In aerosol form, the ancestral strain had a half-life of about 3.2 hours, meaning half the viral particles were still viable after that time. Some variants lasted even longer: the Alpha variant had an aerosol half-life of roughly 6 hours. On plastic surfaces, the half-life ranged from about 3.5 hours (Omicron) to nearly 6 hours (Beta variant), depending on the strain.
This environmental durability supported multiple transmission routes. While airborne spread turned out to be the dominant pathway, the virus’s ability to survive on surfaces for hours added another channel, particularly in indoor settings with poor ventilation. Many common cold viruses lose viability on surfaces much faster, and influenza’s aerosol half-life is generally shorter, which partly explains why COVID spread so efficiently in crowded indoor spaces like restaurants, gyms, and offices.
Higher Fatality Than Seasonal Flu
Global case fatality rates for COVID-19 dropped significantly over the course of the pandemic, from about 2.4% in the early months to around 0.9% by 2023, thanks to vaccines, treatments, and population immunity. Seasonal influenza, by comparison, typically kills about 0.1% of those infected. Even at its lowest, COVID’s fatality rate remained several times higher than flu’s.
The numbers also varied sharply by geography and income. High-income countries reported the highest infection rates (about 35% of the population cumulatively) but the lowest fatality rates (0.6%), reflecting better access to healthcare and vaccines. Low-income countries had far fewer confirmed infections (0.6% of the population) but the highest fatality rate (1.6%), likely due to limited medical resources and underreporting of milder cases. Africa’s cumulative case fatality rate of 2% was ten times higher than Oceania’s 0.2%.
Long-Term Symptoms at an Unusual Scale
Perhaps the most distinctive feature of COVID-19 is the frequency with which it causes prolonged symptoms. While post-viral fatigue syndromes exist after other infections, including flu and mononucleosis, the sheer number of COVID survivors reporting persistent problems drew attention to what became known as long COVID. Symptoms lasting beyond 12 weeks, including fatigue, brain fog, shortness of breath, and heart palpitations, affected a substantial portion of those infected, including many with initially mild illness.
The mechanisms likely tie back to several features already described: the virus’s ability to invade multiple organ systems, its disruption of normal immune signaling, and the widespread presence of ACE2 receptors in tissues beyond the lungs. Damage to blood vessel linings, persistent low-level inflammation, and possible viral reservoirs in tissues like the gut are all under investigation as explanations for why recovery from this particular virus takes so much longer than what most people experience after a typical respiratory infection.